Kurt J. Hilzinger, Director at Outlook Therapeutics, Inc. (OTLK), bought 400,000 shares at $0.44 ($177K) on 2026-05-26, disclosed to the SEC on 2026-05-27.
Open-market purchase of $177k OTLK by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| Filing → |
| OTLK | BUY | 2022-03-03 | $47K | — | Filing → |
| OTLK | BUY | 2022-02-28 | $130K | — | Filing → |
| OTLK | BUY | 2022-02-23 | $514K | — | Filing → |